SCHEMBL21200520

SCHEMBL21200520

Cn1cnnc1CC1(c2cccc(NC(=O)c3cc(CN4CC[C@H](O)C4)nc(C4CC4)n3)c2)COC1

nearest known ligand 0.74

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ CBLB Q13191 20/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29866913 1.00 CBLB (0.74) CBLB
SCHEMBL21200202 0.94 CBLB (0.75) CBLB
SCHEMBL21200205 0.94 CBLB (0.75) CBLB
SCHEMBL29866905 0.94 CBLB (0.75) CBLB
SCHEMBL21200212 0.92 CBLB (0.78) CBLB
SCHEMBL29867718 0.92 CBLB (0.78) CBLB
SCHEMBL29867318 0.91 CBLB (0.77) CBLB
SCHEMBL21200940 0.91 CBLB (0.77) CBLB
SCHEMBL21201324 0.86 CBLB (0.81) CBLB
SCHEMBL29866734 0.86 CBLB (0.81) CBLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3743063-A1 INHIBITORS OF CBL-B AND METHODS OF USE THEREOF Nurix Therapeutics, Inc. (US) 2020-12-02 — — EP disclosed
WO-2019148005-A1 INHIBITORS OF CBL-B AND METHODS OF USE THEREOF NURIX THERAPEUTICS, INC. (US) 2019-08-01 — — WO disclosed
Send feedback